Congratulations to our CEO, President and Founder, Dr. Emil Kakkis, on being honored as BIO’s 2019 Henri A. Termeer Biotechnology Visionary Award recipient for his transformative work in rare diseases. Read more.
October 14,
2019
Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders
October 2,
2019
Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit
September 30,
2019
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita® (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH)